biotech · Sleep · T-Cell Acute Lymphoblastic Leukemia/Lymphoma · BEAM
Beam Therapeutics
Beam Therapeutics is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker BEAM. Primary therapeutic focus areas include Sleep, T-Cell Acute Lymphoblastic Leukemia/Lymphoma, Sickle Cell D
Cambridge, USA HQ
2017 Founded
573 Employees
Public company Type
BEAM · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 573
- Programs
- 10
- Drugs
- 14
- Patents
- 14
BEAM-301: Single dose of BEAM-301 administered by IV
Phase 2 · small molecule · Glycogen Storage Disease Type Ia
BEAM-301: Single dose of BEAM-301 administered by IV for Glycogen Storage Disease Type Ia is a Phase 2 program (small_molecule) at Beam Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code BTX-301-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Beam Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Glycogen Storage Disease Type Ia
- Status
- active
- Trials
- 1